Medication options are available to help manage the cognitive and behavioral symptoms of dementia and Alzheimer's disease.

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily ...

The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by ...